Analyst consensus rating

vTv Therapeutics Analyst Rating: Strong Buy

Direct answer

vTv Therapeutics's consensus rating is Strong Buy.

7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $56.00.
Forecast evidence checked November 16, 2026.

Get free vTv Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$19.69
Average price target
$56.00
High price target
$67.00
Low price target
$42.00
Low target gap
+113.3%
Target upside
+184.4%
High target gap
+240.3%
Target range width
127%
Consensus rating
Strong Buy
Analysts
7
Evidence date
November 16, 2026
Valid through
November 23, 2026

Read the frequently asked questions.

What is the analyst consensus rating for vTv Therapeutics?

vTv Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $56.00.

How far are vTv Therapeutics's low and high targets from the recorded price?

The low target implies +113.3%, while the high target implies +240.3%.

How many analysts are included in vTv Therapeutics's consensus?

The verified consensus includes 7 analysts.

How is vTv Therapeutics's target upside or downside calculated?

The average target of $56.00 is divided by the recorded price of $19.69, then one is subtracted to produce +184.4%. This does not guarantee a future return.

When was vTv Therapeutics's analyst forecast verified?

The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.